Johnson & Johnson ends eczema drug trial after weak results

Johnson & Johnson scrapped a mid-stage trial of its investigational eczema drug JNJ-5939 after an interim review showed it failed to meet high-bar efficacy targets, though it was well tolerated. The company said it will continue advancing other atopic dermatitis candidates in its pipeline.